The data show more reported grade 3C5 adverse events in patients aged??70?years and a trend towards a higher incidence of irAEs requiring treatment with immune-modulating medication in this group
The data show more reported grade 3C5 adverse events in patients aged??70?years and a trend towards a higher incidence of irAEs requiring treatment with immune-modulating medication...